Skip to main content
. Author manuscript; available in PMC: 2013 Aug 20.
Published in final edited form as: J Control Release. 2012 Jun 15;162(1):102–110. doi: 10.1016/j.jconrel.2012.06.008

Figure 7.

Figure 7

Efficacy of NP treatments compared to si-Nectin or si-UL29 lipoplexes, reverse sequence si-Nectin 3:1 NPs, or PBS, using the three dose delivery regimen. Prolonged survival and the lowest clinical disease score were observed in mice receiving NPs encapsulating si-Nectin, relative to all other groups. (A) Percent survival of mice and (B) disease assessment score with respect to time. Disease severity and progression were evaluated as previously described. Error bars represent standard error of the mean.